Figure 1: IL-13 Expression Precedes Pulmonary Dysfunction







Figure 2: 13C5.5 is Derived from a Hybridoma with a Unique Epitope and Lineage






		Affinity, K_D (nM)		Potency, IC_{50} (nM)		
Clone #	Isotype	hIL-13wt	hIL-13v	hIL-13wt	hIL-13v	Cyno IL-13
5G1	IgG1κ	0.008	0.130	0.076	0.048	0.612
13C5 (13C5.5)	IgG1κ	0.075	0.076	0.190	0.170	0.900
9C11	IgG1κ	0.112	0.092	0.184	0.170	0.640

Figure 3: 13C5.5 Neutralizes IL-13 in the Lung





Species	In vitro potency	Affinity	In vivo potency# µg/ml	
	A549 Bioassay IC50 (nM)	Biacore KD (nM)	IL-13 induced AMCase	
			EC_{50}	EC_{95}
Human	0.08 ± 0.02	0.05± 0.001	10.2 ± 2.6	151 ± 27.4
Cyno	4.11 ± 0.4	1.45 ± 0.5	84 ± 17.3	561 ± 117.1
Rat	12.4 ± 0.9	4.0 ± 0.1	536.8 ± 164.3	6763 ± 1190

51D9 inhibition of OVA induced AMCase & AHR: EC_{50} - 34.9 & 22.1 µg/ml

Figure 4: Schematic of First-in-Human (FIH) Dosing




Figure 5: Mean ± SD 13C5.5 Serum Concentration-Time Profiles After Single 0.3 mg/kg,1.0 mg/kg, 3.0 mg/kg and 10 mg/kg IV Infusions of 13C5.5 to Healthy Subjects, Linear Scale




Figure 6: Pharmacokinetic Parameters of 13C5.5

- Pharmacokinetics were dose linear over the range in HV




Figure 7: Mean ± SD 13C5.5 Serum Concentration-Time Profiles Following Single 0.3 mg/kg, 3.0 mg/kg and 10 mg/kg IV Infusions of 13C5.5 to Healthy and Asthma Subjects, Linear Scale




Figure 8: Pharmacokinetic Parameters of 13C5.5

- Pharmacokinetics were similar between HV and subjects with mild/moderate asthma
- Mean half-life ranges from approximately 16.2 ± 9.24 days to 26.0 ± 4.93 day




Figure 9: Pharmacokinetic Parameters of 13C5.5

- 13C5.5 were dose linear in Cmax and AUC in HV; increase in $t_{1/2}$ over dose
- Small increase in Cmax (1.4) and AUC (1.4) over the 33-fold dose range in asthmatics




Figure 10: Pharmacokinetic Parameters of 13C5.5

- Bioavailability following SC administration was estimated to be ~70%
- The accumulation appears to be linear as the Cmax and AUC values are approximately 3-fold greater between doses




Figure 11: Mean ± SD Dose Normalized Cmax Values Following 3 Weekly 0.3 mg/kg (Group 8) and 3.0 mg/kg (Group 9) SC Injections of 13C5.5 (Part 3)




Figure 12: Mean ± SD Dose Normalized AUC0-168 Values Following 3 Weekly 0.3 mg/kg (Group 8) and 3.0 mg/kg (Group 9) SC Injections of 13C5.5 (Part 3)

